ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dimethyl Fumarate

Also written as “dimethyl fumarate”, “BG00012” and “FP187”.

Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis · Psoriasis · Multiple Sclerosis, Chronic Progressive · Arthritis, Rheumatoid, led by 3 companies.

Drug pageDimethyl Fumarate: every studyAll 59 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 9, 201337 company-led studies, 1 open or runningNext primary completion: Jul 28, 2034 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen331 open or runningphase 4since May 9, 2013Sep 9, 2005Jul 28, 2034phase 3 · NCT07483632
Almirallits history only20 open or runningphase 3since Nov 12, 2012Nov 12, 2012none ahead
Forward-Pharmaits history only20 open or runningphase 3since Mar 19, 2013Sep 24, 2010none ahead

Also a collaborator on its studies: GB Pharma Services & Consulting s.r.l., Almirall Hermal and Harrison Clinical Research.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Biogen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 17 studies since Sep 9, 2005.

  1. Apr 25, 2014Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT02125604 · 214 enrolled · Germany
  2. Jun 20, 2014Phase 1 study in HealthyNCT02171208 · 80 enrolled · United States
  3. Nov 3, 2014Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT02283853 · 156 enrolled · United States, Belgium, Bulgaria and more
  4. Jan 9, 2015Phase 4 study in Multiple SclerosisNCT02343159 · 84 enrolled · United States
  5. Apr 2, 2015Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT02410200 · 22 enrolled · United States, Belgium, Bulgaria and more
  6. Apr 23, 20153 phase 3 studiesNCT02428231, NCT02428218, NCT02430532
  7. May 11, 2015Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT02472938
  8. Jun 11, 2015Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT02471560 · 36 enrolled · Norway
  9. Jul 10, 2015Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT02525874 · 218 enrolled · United States, Belgium, Bulgaria and more
  10. Sep 17, 2015Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT02555215 · 20 enrolled · United States, Belgium, Bulgaria and more
  11. Oct 16, 2015Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT02579681 · 221 enrolled · Italy
  12. Mar 7, 2019Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNCT03870763 · 11 enrolled · United States, Colombia, Estonia and more
  13. Dec 12, 2022Phase 4 study in Multiple SclerosisNCT05658484 · 60 enrolled · China
  14. Feb 26, 2026Phase 3 study in Relapsing Forms of Multiple SclerosisNCT07483632 · 185 planned

Ahead

  1. Jul 28, 2034Primary completion: phase 3 study in Relapsing Forms of Multiple SclerosisNCT07483632

TargetBeta

KEAP1 →read by rule
“Kelch-like ECH-associated protein 1 inhibitor”ChEMBL 37, by rule

Other programs on KEAP1

ProgramCompanyFurthest phaseStudies
diroximel fumarateruleBiogenphase 35

Studies

All 33 Biogen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07483632Relapsing Forms of Multiple Sclerosis3Not yet recruitingJul 28, 2034185
NCT05658484Multiple Sclerosis · China4CompletedMar 27, 202560
NCT03870763Multiple Sclerosis, Relapsing-Remitting · United States, Colombia, Estonia and more3TerminatedJul 21, 202211
NCT02579681Multiple Sclerosis, Relapsing-Remitting · Italy3CompletedDec 21, 2016221
NCT02555215Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more3CompletedSep 24, 201820
NCT02525874Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more3CompletedApr 24, 2017218
NCT02471560Multiple Sclerosis, Relapsing-Remitting · Norway4CompletedJun 12, 201736
NCT02472938Multiple Sclerosis, Relapsing-Remitting4WithdrawnJul 20190
NCT02430532Multiple Sclerosis, Chronic Progressive · United States, Belgium, Czech Republic and more3TerminatedJan 201658
NCT02428231Multiple Sclerosis · United States, Belgium, Czech Republic and more3TerminatedDec 201562
NCT02428218Multiple Sclerosis, Relapsing-Remitting3WithdrawnJan 20270
NCT02410200Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more2CompletedSep 23, 201622
NCT02343159Multiple Sclerosis · United States4TerminatedApr 15, 201684
NCT02283853Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more3CompletedJul 8, 2025156
NCT02171208Healthy · United States1CompletedJul 201480
NCT02125604Multiple Sclerosis, Relapsing-Remitting · Germany4CompletedFeb 2016214
NCT02097849Relapsing Forms of Multiple Sclerosis · United States2CompletedMay 2, 201671
NCT02090348Multiple Sclerosis, Relapsing-Remitting4WithdrawnOct 20170
NCT01930708Multiple Sclerosis, Relapsing-Remitting · Austria, Belgium, Canada and more4CompletedMar 31, 20161,114
NCT01924832Healthy · United Kingdom1CompletedApr 201432
NCT01873417Relapsing Forms of Multiple Sclerosis · United States4CompletedNov 2013237
NCT01838668Multiple Sclerosis, Relapsing-Remitting · Czechia, Japan, Korea, Republic of and more3CompletedJun 16, 2015225
NCT01568112Healthy · United States3CompletedOct 2012173
NCT01453426Healthy · Australia, China1CompletedApr 201271
NCT01281111Healthy · United States1CompletedMar 18, 201156
NCT01156311Multiple Sclerosis, Relapsing-Remitting · United States2CompletedMar 2012108
NCT01069913Healthy1CompletedOct 200914
NCT00837785Multiple Sclerosis, Relapsing-Remitting · Germany1CompletedOct 31, 200948
NCT00835770Multiple Sclerosis, Relapsing-Remitting · United States, Australia, Austria and more3CompletedNov 8, 20191,736
NCT00810836Arthritis, Rheumatoid · Australia, Canada, Czech Republic and more2CompletedFeb 2010153
NCT00451451Multiple Sclerosis, Relapsing-Remitting · United States, Belarus, Belgium and more3CompletedAug 20111,417
NCT00420212Multiple Sclerosis, Relapsing-Remitting · United States, Australia, Austria and more3CompletedFeb 20111,234
NCT00168701Multiple Sclerosis · Czechia, Germany, Hungary and more2CompletedMar 31, 2006260

How it is read

Names in the registry

  • “dimethyl fumarate”, 19 entries
  • “BG00012”, 8 entries
  • “FP187”, 5 entries
  • “Dimethyl Fumarate”, 2 entries
  • “Dimethyl fumarate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.